The Heart Failure Society of America's annual HF STATS report paints a bleak picture: heart failure prevalence among U.S. adults is expected to climb from 7.7 million today to 11.4 million by 2050, driven by an aging population and rising cardiometabolic risk factors. Mortality is also trending upward, with age-adjusted rates rising roughly 37% between 2010 and 2023, a reversal of more than a decade of improvement.
The report highlights a particularly troubling shift toward younger adults. From 2001 to 2020, unadjusted heart failure mortality more than doubled among people ages 25–44 and nearly doubled among those 45–64, even as hospitalization rates declined in older adults. The authors call for earlier risk-factor screening and control, including greater use of risk scores and natriuretic peptide testing in stage B heart failure.
A central concern is the profound underuse of guideline-directed medical therapy. Real-world data show that only 18% of more than 3 million patients with heart failure with reduced ejection fraction receive all four recommended drug classes. Editorialists urge implementation strategies such as EHR-based decision support, multidisciplinary programs, and simplified regimens to close the gap between evidence and practice.